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ABSTRACT During visceral leishmaniasis, the control of hepatic parasite burden is mainly due to granuloma assembly in a mi-
croenvironment consisting of both Th1 and Th2 components. Using enzyme-linked immunosorbent assay (ELISA) dosages,
quantitative PCR (qPCR), immunohistochemistry, and flow cytometry, we studied the role of interleukin-33 (IL-33), a recently
described cytokine signaling through the ST2 receptor, during visceral leishmaniasis. We showed that a higher level of IL-33 was
detected in the serum of patients with visceral leishmaniasis than in that from healthy donors and demonstrated the presence of
IL-33 cells in a liver biopsy specimen from a patient. Similarly, in BALB/c mice experimentally infected with L. donovani, a
higher level of IL-33 was detected in the serum, as well as the presence of IL-33 cells and ST2 cells in the mouse liver. In
ST2/ BALB/c mice, better control of the hepatic parasite burden and reduced hepatomegaly were observed. This was associ-
ated with strong induction of Th1 cytokines (gamma interferon [IFN-] and IL-12) compared to the level in wild-type (WT) mice
and better recruitment of myeloid cells associated with strongly induced chemokines (CCL2 and CXCL2) and receptors (CCR2
and CXCR2). Conversely, BALB/c mice treated twice weekly with recombinant IL-33 showed a dramatically reduced induction of
Th1 cytokines and delayed inhibition of monocyte and neutrophil recruitment in the liver, which was associated with reduced
KC/CXCL1 and CXCR2 expression. Taken together, our results suggest that IL-33 could be a new deleterious regulator of the
hepatic immune response against Leishmania donovani, via the repression of the Th1 response and myeloid cell recruitment.
IMPORTANCE Visceral leishmaniasis is a life-threatening systemic disease due to the Leishmania protozoa L. infantum and
L. donovani and is ranked by the World Health Organization as the second most important protozoan parasitic disease after
malaria for its grave morbidity, high mortality, and global distribution. Leishmania parasites subvert the host’s immune re-
sponse to propagate to target organs, including the spleen, the bone marrow, and the liver. Control of hepatic parasite burdens
depends on a delicate and poorly understood Th1/Th2 immune balance. To better understand this complex immune response,
new cytokines are interesting targets for research studies. IL-33 is a newly described cytokine usually associated with Th2 re-
sponse and involved in different diseases, including infectious diseases and hepatitis. Our results suggest that IL-33 could be a
new factor of susceptibility and a potential prognostic marker during visceral leishmaniasis.
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Interleukin-33 (IL-33) is a recently identified member of the IL-1cytokine family that can act either as a nuclear binding factor or
as a cytokine (1, 2). Once secreted, IL-33 signals through a het-
erodimer composed of the ST2-specific receptor (also called T1 or
IL-1RL1) and the IL-1 receptor accessory protein, which is a
member of the IL-1 receptor family (2). Before the discovery of
IL-33, ST2 was known as a Th2 cell marker constitutively ex-
pressed or induced on several immune cell types, such as Th2
lymphocytes, invariant natural killer T (iNKT) cells, natural killer
(NK) cells, cytotoxic T cells, monocytes, macrophages, dendritic
cells, polymorphonuclear neutrophils (PMN), mast cells, baso-
phils, and eosinophils (3). Accordingly, IL-33 has a broad range of
effects on the immune system— either proinflammatory effects or
promotion of Th2 immune response—leading to beneficial or
worsening outcomes, depending on the clinical setting (4, 5).
IL-33 plays a deleterious role in many autoimmune diseases, such
as rheumatoid arthritis (6, 7) and inflammatory bowel disease (8),
and induces a predisposition to asthma and other allergic diseases
(9, 10). Conversely, IL-33 has a protective role in many diseases
associated with or exacerbated by Th1 response, like atherosclero-
sis (11), and in some cardiovascular or metabolic diseases (12, 13).
During infectious diseases, IL-33 may also play opposing roles,
depending on the organ involved and the Th1/Th2 immune bal-
ance necessary to control the infection. IL-33 was shown to be
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protective during sepsis (14) or keratitis due to Pseudomonas
aeruginosa (15) and during infections with Trichuris muris (16),
Schistosoma mansoni (17), or Toxoplasma gondii (18), whereas it is
deleterious during cutaneous leishmaniasis (CL). In Leishmania
major-infected mice, it was demonstrated that a minor population
of ST2 Th2 cells were specifically enriched in the nonhealing
infection site (19) and that blockade of ST2 using an ST2-specific
blocking antibody or the fusion protein T1-Fc resulted in the de-
velopment of less severe disease, with reduced parasite load and a
switch in T cell response polarity to a protective Th1 response
(20).
During visceral leishmaniasis (VL) due to L. infantum and
L. donovani, the control of hepatic parasite burden is mainly due
to a granulomatous inflammatory response, mostly involving
Kupffer cells and infiltrating blood monocytes (21). In experi-
mental models of VL, IL-12 plays a pivotal role by initiating a Th1
cell response with the production of gamma interferon (IFN-),
which activates macrophages, leading to parasite death (22).
However, regarding its sustained exposure to many antigens and
chemicals, the liver is characterized by a tolerogenic Th2-biased
microenvironment, with IL-10 and transforming growth factor 
(TGF-) secretion (23). Thus, a peculiar immune environment
involving both Th1 and Th2 cells is usually described during VL
and is associated with efficient granuloma assembly and parasite
killing (24, 25). Recently described cytokines could be involved in
this complex hepatic immune response.
Whereas ST2 is clearly associated with the
deleterious Th2 response against L. major
in the skin during cutaneous leishmania-
sis (20), no data are available about the
roles of IL-33 and ST2 in the liver during
VL. Here, we show that IL-33 and ST2 are
expressed in the liver during human and
experimental murine VL. ST2 deficiency
in transgenic BALB/c mice led to a better
controlled parasite burden in the liver,
which was associated with an early infil-
trate of PMN and monocytes and a Th1
polarized immune response. Conversely,
injection of recombinant IL-33 in BALB/c
mice led to a repressed Th1 response and
limited infiltrate of PMN and monocytes.
RESULTS
Human visceral leishmaniasis is associ-
ated with increased serum IL-33 and
IL-33 expression in the liver. IL-33 was
detected at significantly higher levels in
the serum of the 6 VL patients than in the
21 healthy controls (41.8 13.5 pg/ml
versus 8.6 2.2 pg/ml; P  0.0105)
(Fig. 1A). All dosages were carried out be-
fore onset of treatment.
Immunohistochemical staining of the
liver biopsy specimen obtained from a pa-
tient with VL revealed a huge parasite
burden associated with numerous IL-33-
positive cells— either endothelial cells or
infiltrating cells and cells surrounding
granulomatous foci (Fig. 1B). These ob-
servations led us to further investigate the
role of IL-33 in murine models.
Infection with L. donovani is associated with increasing lev-
els of serum IL-33 and IL-33 expression in the liver. IL-33 levels
were measured in the serum of BALB/c mice infected with L. don-
ovani at different time points of the disease, and the results re-
vealed a low level of detection in noninfected mice (3.4 1.8 pg/
ml), as well as at day 15 (D15) and D30 postinfection (2.4 2.3
and 4.1 4.1 pg/ml, respectively). A significant increase in IL-33
was detected in the serum at day 60, with a mean concentration of
89.7 20.1 pg/ml (P  0.05 compared with D0, D15, and D30)
(Fig. 1C).
As for humans, immunohistochemical staining of liver biopsy
specimens using a goat anti-mouse IL-33 revealed the presence of
a specific nuclear staining in cells preferentially located in granu-
lomas and infiltrates surrounding blood vessels at D60 (Fig. 1D),
and to a lesser extent at D15 and D30 (data not shown). In addi-
tion, as classically described, some endothelial cells were also IL-
33 (2, 26), as confirmed via a costaining of IL-33 and CD31 by
immunofluorescence on frozen liver sections at all time points
(data not shown).
Infection with L. donovani induces the recruitment of ST2
cells in the livers of BALB/c mice. In order to study the impact of
this IL-33 hepatic expression and late systemic secretion, the pres-
ence of ST2-expressing cells was first demonstrated by immuno-
FIG 1 Dosage of serum IL-33 and IL-33 hepatic expression in patients with visceral leishmaniasis and
in BALB/c mice infected with Leishmania donovani. (A) Quantification of IL-33 by ELISA in the serum
of VL patients (n  6) and healthy donors (n  21); the data represent means  SEM (*, P  0.05). (B)
IL-33 expression detected by immunohistochemistry in the liver of a VL patient. The image was ac-
quired at a 400 magnification. (C) Quantification of IL-33 by ELISA in the serum of BALB/c mice
infected with L. donovani at 15, 30, or 60 days postinfection (D15, D30, and D60, respectively) and of
noninfected mice (D0); the data represent means  SEM from 4 mice per time point (*, P  0.05). (D)
IL-33-expressing cells detected by immunohistochemistry on a liver section from an infected BALB/c
mice (D60). Shown is a representative image acquired from 1 mouse out of 7 at a 400 magnification.
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histochemistry in the liver at D60 (Fig. 2A). A flow cytometry
analysis of the whole liver using the same antibody revealed spe-
cific ST2 expression in CD11b GR1int cells and in CD19 cells
compared with the isotype control antibody (Fig. 2B). Indeed, the
mean fluorescent intensity (MFI) ratios of the anti-ST2 antibody
and isotype were 2.2 and 2.3, respectively, and significantly differ-
ent from 1, whereas other analyzed cell populations showed lower
and nonsignificant ratios (Fig. 2C). On day 60 after infection, no
significant change was observed in the MFI ratio for any cell type
(Fig. 2C). However, a significant infiltrate of all analyzed cell types
was observed at D60 compared to noninfected mice, with a 5.5-
fold increase of CD11b GR1int cell number in the total liver,
whereas other cell types were only 2.5- to 3.8-fold increased
(Fig. 2D), leading to an enrichment of ST2 cells after infection.
The hepatic Leishmania burden is better controlled in
ST2/ BALB/c mice. To address the role of the ST2 infiltrating
cells, the hepatic immune responses were compared in wild-type
(WT) and ST2-deficient mice after infection with L. donovani. In
WT mice, the parasite burden was significantly higher at D60
(757.0  125.3 L. donovani units [LDU]), compared with D15 and
D30 (399.4 76.86 and 389.5  73.67 LDU, respectively). In
ST2/ mice, the parasite burden was similar to that of WT mice
at D15 and D30, but at D60, the liver parasite burden was signifi-
cantly lower in ST2/ mice (400.8  69.62 LDU) than in WT
mice (P  0.05) (Fig. 3A).
The uncontrolled parasite burden in BALB/c mice at D60 was
associated with significant hepatomegaly, a common feature of
VL. Indeed, the weight of the liver reached 1.4  0.1 g at D60 and
was significantly increased compared with that in noninfected
mice (1.1  0.1 g; P  0.05). The basic liver weight of noninfected
ST2/ mice was comparable to that of noninfected WT mice, but
at D60 it was significantly lower in ST2/ mice than that in WT
mice (1.0  0.1; P  0.05) (Fig. 3B).
ST2/ mice infected with L. donovani display a Th1 polar-
ized immune response. As the hepatic immune response against
L. donovani is highly dependent on cytokine induction, quantita-
tive PCR (qPCR) analyses were performed on hepatic lysates to
quantify the induction of key Th1 and Th2 cytokines. Whereas
IL-12p35 was not significantly induced in WT mice during the
course of the disease, strong induction was observed in ST2/
FIG 2 ST2 expression in the liver of BALB/c mice infected with Leishmania donovani. (A) Detection of ST2 cells by immunohistochemistry in liver section of
an infected BALB/c mouse on day 60 (D60) postinfection. Shown is a representative image acquired from 1 mouse out of 7 at a 400 magnification. (B, C, and
D) Quantification of ST2 cell infiltrate in the total livers of BALB/c mice by flow cytometry in noninfected mice (D0) or infected mice at D60. (B) ST2 receptor
was detected in GR1int CD11b cells and CD19 cells. The gray curve represents the control isotype, and the black curve represents the specific ST2 staining. This
panel is representative of 3 to 4 mice per group. (C) Quantification of ST2 expression on each cell type. ST2 expression was computed as the ratio of ST2/control
Ig-FITC mean fluorescence intensities (MFI). The ratio was annotated with * when significantly higher than 1 (P  0.05). (D) Absolute quantification of each cell
type in the total liver of mice at D0 and D60. The data represent means  SEM from 4 mice per time point (*, P  0.05).
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mice at D15 and D60 (P  0.01 and P  0.05, respectively)
(Fig. 4A). Similarly, IFN- was not significantly induced in in-
fected WT mice compared to noninfected mice, but a significant
induction was observed in ST2/ mice at early and late time
points (P  0.05) (Fig. 4B). On the contrary, Th2 cytokines, such
as IL-4, IL-10, and IL-13, were not induced or were weakly in-
duced, and there were no significant differences between infected
and noninfected mice (data not shown).
Monocytes and PMN are recruited early in the liver of
ST2/ BALB/c mice in response to L. donovani infection. As
monocytes and PMN are important cell types recruited early in
the liver for an efficient immune response against L. donovani,
some key chemokines involved in their attraction, CCL2 and
CXCL2, were quantified by qPCR. A significant elevation in CCL2
mRNA was observed at D15 (P  0.05) and D30 (P  0.01) in the
ST2/ samples compared to those from WT mice (Fig. 5A). A
significant rise in CXCL2 expression was also observed in ST2/
mice at D30 (P  0.001), with significantly stronger induction
than in WT mice (P  0.05) (Fig. 5B).
To quantify the recruitment of CCL2- and CXCL2-responding
cells, the induction of CCR2 and CXCR2 receptors was analyzed
by qPCR in hepatic lysates. CCR2 was not perceptibly induced in
WT mice, whereas a significantly higher induction was observed
in ST2/ mice at D15 (P  0.05) and D30 (P  0.01) (Fig. 5C).
Similarly, a significant induction of CXCR2 was observed at D15
in ST2/ mice compared to that in WT mice (P  0.001)
(Fig. 5D).
To address the role of CCL2 and CXCL2 to recruit myeloid
cells in the liver during the course of infection, the expression of
myeloperoxidase (MPO) was quantified by qPCR in the liver. The
expression of this enzyme, mostly expressed in PMN, was higher
in ST2/ mice at all time points after infection (P  0.05 at D30)
(Fig. 5E). To confirm the stronger myeloid cell recruitment in
ST2/ mice, an immunohistochemical staining using an anti-
MPO antibody was performed on liver sections. The number of
MPO cells observed on tissue sections was expressed in terms of
the tissue surface (mm2). A striking infiltrate of MPO cells was
observed at D15 and D30 (P  0.05) in ST2/ mice (Fig. 5F to
H). In particular, an early infiltrate was observed at D15, where the
number of MPO cells was 2-fold higher in ST2/ mice com-
pared to WT mice (P  0.05) (Fig. 5F), but no significant differ-
ence was observed between WT and ST2/ mice at later time
points (Fig. 5F).
Recombinant IL-33 treatment limits the Th1 immune re-
sponse in infected BALB/c mice. In order to consolidate the data
obtained with ST2-deficient mice and address more specifically
the role of free IL-33 in the liver, BALB/c WT mice were infected
with L. donovani and treated intraperitoneally with recombinant
IL-33 (rIL-33) twice a week until sacrifice on day 15, 30, or 60.
A dramatic reduction of hepatic IFN- and IL-12p35 induc-
tion was observed in rIL-33-treated mice compared to nontreated
(NT) mice (P  0.001 and P  0.05 on day 60, respectively)
(Fig. 6A and B). Again, no differences were observed in the induc-
tion levels of the Th2 cytokines IL-4, IL-10, and IL-13 at all time
FIG 3 Hepatic parasite burdens and liver weights in BALB/c WT and ST2/
mice after infection with Leishmania donovani. (A) Liver parasite burden was
determined on days 15, 30, and 60 postinfection (D15, D30, and D60, respec-
tively) by microscopic counting of Giemsa-stained tissue sections and is ex-
pressed as LDU (no. of parasites/1,000 nuclei  liver weight in mg). (B) The
liver weight was recorded on days 0, 15, 30, and 60 in WT and ST2/ mice.
Data are expressed as means  SEM from 7 to 13 mice per mouse strain for
each time point; pooled data are from three independent experiments (*, P 
0.05).
FIG 4 Kinetics of hepatic mRNA induction of IL-12 and IFN- in WT and
ST2/ mice infected with Leishmania donovani. mRNA induction of IL-12
(A) and IFN- (B) was quantified by quantitative PCR in liver extracts at
various time points after infection and normalized by comparison to 18S
mRNA. Data are the means  SEM from 7 to 13 mice per mouse strain for each
time point; pooled data are from three independent experiments (*, P  0.05;
**, P  0.01).
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points (data not shown), suggesting a specific Th1 repression in
the livers of BALB/c mice in response to IL-33. Additionally, a
mild increase in parasite loads was observed in treated mice com-
pared to NT mice (380 27 versus 528 83 LDU on day 30,
respectively, and 450 58 versus 685 193 LDU on day 60; P not
significant) (Fig. 6C).
Treatment of BALB/c mice with
rIL-33 inhibits the hepatic recruitment
of monocytes and PMN after infection
with L. donovani. Quantitative analysis
of chemokine mRNA in liver lysates
showed a significant induction of CCL2 at
D15, D30, and D60 and of CXCL2 at D15
and D30 (P  0.05), but the kinetics were
surprisingly similar between NT and rIL-
33-treated mice for both chemokines
(Fig. 7A and B).
The induction of chemokine receptors
was also analyzed. A significant induction
of CCR2 was observed at all time points
(P  0.05 at day 15 and P  0.01 at day
60), with no obvious difference between
NT and rIL-33-treated mice (Fig. 7C).
CXCR2 was also significantly induced in
both NT and rIL-33-treated mice (P 
0.01 and P  0.05, respectively), but to a
lesser extent at D30 and D60 in rIL-33-
treated mice (P  0.05 between both
groups of mice at day 60) (Fig. 7D). The
discrepancy of reduced CXCR2 but un-
modified expression of CXCL2 in rIL-33-
treated mice led us to investigate KC ex-
pression, since KC-responding cells also
express CXCR2. This chemokine was in-
deed significantly induced in the liver of
NT mice at D15, D30, and D60 (P 
0.05), whereas it was significantly re-
pressed at D60 in treated mice compared
to the level in NT mice (P  0.001)
(Fig. 7E).
To analyze the impact of KC and
CXCL2 repression in rIL-33-treated mice,
infiltrating MPO cells were counted on
liver sections stained by immunohisto-
chemistry. As expected, significant re-
cruitment of MPO cells was observed in
NT mice at D30 and D60 (P  0.05). In
rIL-33-treated mice, the numbers of
MPO cells were similar at D15 and D30
but significantly lower at D60 (P  0.05)
(Fig. 7F to H). Flow cytometry analysis
was performed on infected NT or rIL-33-
treated mice to characterize the presence
of PMN and macrophages in the total
liver during the course of the disease. In
agreement with immunohistochemistry,
no difference was observed between NT
and rIL-33-treated mice at D15 and D30,
but the number of CD11b GR1high cells
was significantly reduced in rIL-33-
treated mice at D60, as was the number of CD11b GR1int cells
(Fig. 7I and J).
Globally, a significant reduction of infiltrate cells was observed
on day 60 for other cell types, such as T cells, B lymphocytes, and
NK cells (Fig. 8A), and this finding is in agreement with the lower
hepatomegaly observed in rIL-33-treated mice (Fig. 8B).
FIG 5 Recruitment of polymorphonuclear neutrophils and monocytes in the livers of WT and ST2/
mice infected with Leishmania donovani. Quantification of mRNA induction of CCL2 (A), CXCL2 (B),
and their corresponding receptors, CCR2 (C) and CXCR2 (D), as well as MPO (E) by qPCR at various
time points after infection and normalized by comparison to 18S mRNA. Data are expressed as means
 SEM from 7 to 13 mice per background for each time point; pooled data are from three independent
experiments (*, P  0.05; **, P  0.01; ***, P  0.001). (F) Quantification of MPO cells detected by
immunohistochemistry using an anti-MPO antibody after microscopic observation. Data represent the
mean number  SEM of MPO cells counted per mm2 of liver section during the course of the disease
in infected WT and ST2/ mice (7 to 13 mice per mouse background for each time point). Represen-
tative fields were observed at 15 days postinfection in WT (G) or ST2/ mice (H) at 100 magnifi-
cation. MPO cells are indicated by black arrows.
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DISCUSSION
IL-33 is a recently described cytokine with involvement in many
diseases (5, 27–30). Our team and others have contributed to the
characterization of IL-33 sources during acute hepatitis (31, 32).
During chronic hepatitis, expression of IL-33 and its receptor,
ST2, is associated with sustained inflammation and Th2 response
leading to liver fibrosis in both mice and humans, with a correla-
tion between IL-33 expression and fibrosis severity (26). As liver
fibrosis is a common feature during visceral leishmaniasis (VL)
(33), we investigated the expression of IL-33 during human VL.
Significant IL-33 release in the serum of VL patients was observed
compared with the level in healthy blood donors, and numerous
IL-33 cells were detected by immunohistochemistry in a liver
biopsy specimen from a patient. Thus, IL-33 could be either a
biomarker of the disease, which could reflect its severity, or a
marker among others of the host defense against Leishmania par-
asites. The large variation in the IL-33 levels in the patients (stan-
dard error of the mean [SEM], 13.50) compared with healthy
donors (SEM, 2.227) suggests a variable release of IL-33, possibly
depending on the severity of the disease, the genetic background
of the patient, the immunologic status and/or other associated
diseases. The place of IL-33 and ST2 as diagnostic or prognostic
tools, as proposed for other diseases (34, 35), should be explored
in a larger and prospective study of VL patients with different risk
factors but also before and after treatment.
To elucidate the role of IL-33 during VL, a BALB/c mouse
model was used. As observed in humans, IL-33 was significantly
increased in the serum of BALB/c mice infected with L. donovani
and was detected in the liver by immunohistochemistry. As ex-
pected, most endothelial cells were IL-33 cells (36), but addition-
ally, numerous IL-33 infiltrating cells were observed in the he-
patic tissue, mainly located in granulomas. This led us to
investigate the effect of IL-33 on the recruitment of ST2 immune
cells in the livers of BALB/c mice. Immunohistochemistry re-
vealed the presence of ST2 infiltrating cells in and around the
granulomas, suggesting a regulatory role for IL-33 signaling via
ST2 in the granulomatous response against L. donovani. Flow cy-
tometry analysis of the liver immune cells showed the presence of
ST2 macrophages and ST2 B lymphocytes in the livers of
BALB/c mice, but no significant increase of ST2 MFI was observed
after infection. However, the important recruitment of mono-
cytes/macrophages (5.5) and B lymphocytes compared to other
immune cell types could account for enrichment in ST2 cells in
the liver after infection. Interestingly, flow cytometry analysis of
the livers of C57BL/6 mice, performed simultaneously, showed
lower levels of ST2 MFI (data not shown). Since C57BL/6 mice
display a preferential Th1 immune response, whereas BALB/c
mice are known to have a Th2-biased genetic background (37),
these data are consistent with the widely recognized function of
ST2 as a marker associated with Th2 response (38–40). As the
balance between Th1 and Th2 responses is critical for VL suscep-
tibility (41–45), we further investigated whether IL-33 could act as
a factor of susceptibility associated with Th2 response. It is note-
worthy that we also observed a significant increase in IL-33 cells
in the spleens of infected BALB/c mice (data not shown), which
can be placed in parallel with the lack of parasite control classically
observed in this organ (46, 47).
ST2-deficient BALB/c mice showed better control of the he-
patic parasite burden than wild-type (WT) congenic controls,
which could result from an exacerbated Th1 response known to be
of prime importance in the control of VL. Indeed, we observed a
switch in favor of Th1 response in the livers of ST2/ mice, with
increased and earlier expression of IFN- and IL-12, both cyto-
kines of utmost importance in the control of infection (22, 48–51).
The levels of expression of Th2 cytokines such as IL-13, IL-10, and
IL-4 did not significantly differ between WT and ST2/ mice
(data not shown). Inversely, rIL-33-treated mice displayed re-
duced IL-12 and IFN- induction, thus strengthening the data
obtained with ST2/ mice. Again, no change in IL-4 and IL-10
expression was observed in the livers of rIL-33-treated mice. These
data suggest that IL-33 could act as a repressor of the Th1 response
during VL, as observed during CL (20), rather than an inducer of
Th2 response, as described during other diseases (17, 52). Addi-
tionally, during this study, we have not been able to demonstrate
any involvement of IL-33 in the regulation of T regulatory (Treg)
cells (data not shown).
FIG 6 Kinetics of hepatic mRNA induction of IL-12 and IFN- and parasite
burdens in BALB/c mice infected with Leishmania donovani and treated with
recombinant IL-33 (rIL-33) or not treated (NT). mRNA induction of IL-12
(A) and IFN- (B) was quantified by quantitative PCR in liver extracts at
various time points after infection and normalized by comparison to 18S
mRNA. Liver parasite burden was determined by microscopic counting of
Giemsa-stained tissue sections, and the results are expressed as LDU (no. of
parasites/1,000 nuclei  liver weight in mg) (C). Data are means  SEM for
each group of mice (4 to 5 mice per treatment group for each time point; *, P
 0.05; ***, P  0.001).
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FIG 7 Recruitment of polymorphonuclear neutrophils and monocytes in the livers of BALB/c mice infected with Leishmania donovani and treated with
recombinant IL-33 (rIL-33) or not treated (NT). Shown is mRNA induction of CCL2 (A) and CXCL2 (B), their respective receptors CCR2 (C) and CXCR2 (D),
and KC/CXCL1 (E) at various time points after infection, normalized by comparison to 18S mRNA. (F) MPO cells were stained by immunohistochemistry and
counted per mm2 of liver section during the course of the disease in infected NT and rIL-33-treated mice. Data are expressed as means  SEM for each group of
mice (4 to 5 mice per treatment group for each time point). Shown are representative fields of MPO cell infiltrates at 60 days postinfection in WT (G) or
rIL-33-treated (H) mice at a 100 magnification. MPO cells are indicated by black arrows. (I and J) Quantification of polymorphonuclear neutrophils (PMN;
CD11b GR1high) (I) and macrophages (CD11b GR1int) (J) in hepatic infiltrates by flow cytometry on the total livers of NT or rIL-33-treated mice. Data are
expressed as means  SEM for each group of mice (4 to 5 mice per treatment group for each time point; *, P  0.05; ***, P  0.001).
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The influx of both monocytes and PMN is necessary for func-
tional granuloma formation and final parasite clearance in the
liver and has been highlighted in several studies (21, 53). Previous
studies by our team and others showed a key role of CCL2,
CXCL2, and KC/CXCL1 in the recruitment of these myeloid cells
and the efficacy of disease control (53–55); thus, we focused on
these chemokines. We observed an earlier and stronger induction
of CCL2 and CXCL2 in ST2/ mice than in WT mice, associated
with a higher induction of their corresponding receptors CCR2
and CXCR2 until day 15. Similarly, rIL-33-treated mice displayed
dramatically impaired induction of CXCR2, although this was
mostly perceptible from day 30 postinfection. This apparent dif-
ference in kinetics is probably linked to these experimental mod-
els, with an early impact of genetic ST2 deficiency on microenvi-
ronmental factors but later effects of long-term treatment with
low rIL-33 dosages. However, no difference in CCL2 and CXCL2
was observed between rIL-33-treated and nontreated mice; thus,
we explored KC/CXCL1 induction, which is also involved in
CXCR2 cell attraction and was indeed dramatically reduced in
rIL-33-treated mice. Overall, these results suggest that besides
CCL2 and CXCL2, KC/CXCL1 is also implicated in the recruit-
ment of MPO cells in the livers of BALB/c mice and can be
downregulated by IL-33. The decrease in monocytes and PMN
influx in the liver in both models was associated with higher he-
patic parasite burdens in WT compared to ST2/ mice (P 
0.05), as well as in rIL-33-treated mice compared to nontreated
ones, although the result was statistically not significant because of
a lack of power (P not significant). This apparent lack of statisti-
cally significant difference in parasite loads could be also related to
the design of our model, using repetitive injections of low doses of
rIL-33 (0.5 g). A treatment using higher rIL-33 dosages and/or
more frequent injections might have allowed the observation of
higher parasite loads in the livers of treated mice. Anyway, the
whole data are in full agreement with our previous observation of
the important role of myeloid cells in the efficacy of parasite clear-
ance (53).
Divergent conclusions can be found in the literature regarding
the role of IL-33 in monocyte and neutrophil recruitment accord-
ing to the model shown in references 14, 28, 56, and 57, but it is
frequently associated with cell attraction during inflammatory
diseases. In contrast, our results are consistent with a recent study
showing that IL-33 is associated with the repression of neutrophil
recruitment, thereby limiting liver damage and disease severity in
an experimental model of liver ischemia and reperfusion (57).
The signaling pathways underlying the downregulation of Th1
effectors in our model remain to be determined. As IL-33 is
known to be a regulator of the NF-B pathway (58), and NF-B is
a key regulator of expression of cytokines, chemokines, and recep-
tors, including IL-12 (59, 60), IFN- (61), KC (62), CCL2 (63),
CXCL2 (64), and CXCR2 (65), which have been identified as be-
ing of major interest in our study, the study of NF-B regulation
by IL-33 in infected cells should be undertaken to better under-
stand the mechanism of action of IL-33 during VL. As a first ap-
proach, we analyzed the NF-Bp65 induction by qPCR on liver
extracts, which revealed significant overexpression in ST2/
BALB/c mice and significant downregulation in rIL-33-treated
mice compared to WT untreated mice (data not shown). These
results suggest that IL-33 could repress the NF-Bp65 expression,
as stated in a previous study (58), in order to counterbalance the
NF-B induction observed in response to Leishmania infection
(66, 67), thus leading to downregulation of chemokines and Th1
cytokines. As IL-33 signaling via ST2 is usually associated with
NF-B activation (2), the apparent downmodulation of NF-
Bp65 expression by IL-33 during L. donovani VL needs further
investigation to better characterize the posttranslational regula-
tion of NF-B pathways in this model.
In conclusion, our results showed that in BALB/c mice, the
IL-33/ST2 pathway does not control L. donovani infection but
instead is associated with the downregulation of the Th1 response
and poorer outcome. The role of IL-33 as a prognostic marker
during VL in humans should be further explored.
MATERIALS AND METHODS
Ethics statement. The study on mouse models was carried out in accor-
dance with the French institutional guidelines (Direction des Services
Vétérinaires, agreement no. 35 to 135) and with EC directive 86/609/CEE.
The use of ST2/ mice in our animal facilities was approved by the
Commission Génie Génétique (Ministère de l’Enseignement Supérieur et
de la Recherche, agreement no. 5387-CA-1), and the protocol was ap-
proved by the local ethical committee (R-2012-JPG-01). Human blood
samples were collected after written informed consent was obtained from
the patients.
Patients. The sera from patients with VL (n  6) and healthy donors
(n  21) were collected for IL-33 dosage. A specimen from a liver biopsy
performed during the diagnosis of one case of VL was also available for
histological analysis with IL-33 staining.
Mice. Female BALB/c wild-type mice were purchased from Janvier
Laboratories (Le Genest-Saint-Isle, France) and acclimatized for at least
10 days before challenge. BALB/c ST2 knockout (ST2/) mice (17) were
backcrossed for at least 10 generations. Mice were bred and housed in our
FIG 8 Liver weight and lymphoid cell influx in BALB/c mice treated with
recombinant IL-33 (rIL-33) or not treated (NT) after infection with Leishma-
nia donovani. (A) Flow cytometry quantification of CD19 B lymphocytes
(BL), CD3 NP46 T cells (TL), NP46 CD3 T NKT cells, and NP46 CD3
NK cells, in the total livers of NT or rIL-33-treated mice. (B) Liver weight over
the course of infection in NT and rIL-33-treated mice on day 60 postinfection.
Data are the means  SEM from each group of 4 to 5 mice for each time point
(*, P  0.05).
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animal facilities. Mice were 7 to 12 weeks old when challenged with L. don-
ovani. Naive congenic mice, matched according to age, were used as non-
infected controls. The results were obtained in three independent exper-
iments, with a total of 7 to 13 mice per time point.
Parasites and infection of mice. The L. donovani strain (MHOM/SD/
97/LEM3427, typed as Zym MON-18 by the Center National de Référence
des Leishmanioses, Montpellier, France) used in this study was main-
tained in vivo by serial murine passages and grown in vitro on Novy-
McNeal-Nicolle (NNN) blood agar at 27°C. Prior to infection, amplifica-
tion of promastigotes was carried out by culture in Schneider’s Drosophila
medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf
serum (FCS), 100 U/ml penicillin, and 100 g/ml streptomycin, for 6 days
at 27°C, until they reached stationary phase. Animals were infected on day
0 (D0) by intraperitoneal injection of 108 promastigotes, and groups of 7
to 13 mice were sacrificed on D15, D30, or D60. Prior to sacrifice, blood
was collected by retro-orbital puncture, and the serum was stored at
80°C. The liver was recovered and weighed, cut into pieces, and then
used for immune cell typing by flow cytometry or formalin fixed and
paraffin embedded or snap-frozen in isopentane-liquid nitrogen for
mRNA extraction.
Treatment with recombinant IL-33. Recombinant IL-33 (rIL-33) was
purchased from PeproTech. Mice (4 to 5 animals per time point) were
infected with L. donovani at D0 as previously described and treated by
intraperitoneal injection of 0.5 g of rIL-33 per mouse twice a week until
the mice were sacrificed at D15, D30, or D60. Nontreated BALB/c mice
were used as controls and infected with the same parasite inoculum.
Serum IL-33 quantification. IL-33 was quantified in the serum of
both humans and mice at a 1:2 dilution using, respectively, the specific
human and mouse Duoset enzyme-linked immunosorbent assay (ELISA)
development systems (R&D Systems), according to the manufacturer’s
instructions, except for the reveal step, in which orthophenyl-dianisidine
was used instead of tetramethylbenzidine. Absorbance was determined at
490 nm using a spectrophotometer, and the results were determined from
a 10-point standard curve, and expressed as pg/ml.
Quantification of liver parasitic burden. Parasite burden was deter-
mined by microscopic examination of Giemsa-stained smears, with the
results expressed as L. donovani units (LDU) (i.e., number of amastigotes
per 1,000-cell nuclei  liver weight in mg) (68).
Immunohistochemical characterization of immune cells in the
liver. Immunohistochemical studies were performed as previously de-
scribed by our team (26, 32, 53). Briefly, mouse myeloperoxidase (MPO)
was stained using polyclonal rabbit anti-MPO antibody diluted 1/1,000
(DakoCytomation), mouse ST2 receptor was stained by immunochemis-
try of liver sections using a rat anti-mouse ST2 antibody diluted 1/100
(DJ8; MB Bioproducts), mouse IL-33 was stained using goat anti-mouse
IL-33 diluted 1/50 (R&D Systems), and human IL-33 was stained using
the Nessy-1 monoclonal antibody diluted 1/50 (Enzo Life Sciences). All
immunohistochemical experiments were performed with the Ventana
Discovery XT robot, using the Ventana DABMap detection kit (Ventana
Medical Systems, Tucson, AZ) with a biotinylated goat anti-rabbit anti-
body diluted 1/700 (Vector Laboratory), a biotinylated donkey anti-rat
antibody diluted 1/100 (Jackson Immune Research), a horse anti-goat
antibody diluted 1/700 (Vector Laboratory), and a horse anti-mouse an-
tibody diluted 1/700 (Vector Laboratory), respectively. The sections were
then counterstained with hematoxylin. Appropriate controls were made
to validate the antibodies: no staining was observed without primary an-
tibodies, and ST2/ and IL-33/ mice showed no ST2 or IL-33 stain-
ing, respectively. The number of MPO cells was counted after micro-
scopic examination and is reported per mm2 using a Zeiss Primo Star
optical microscope. Pictures were obtained with a Nikon 80i optical mi-
croscope equipped with a numerical camera.
RNA isolation and analysis of hepatic gene expression. Total cellular
RNA was extracted and purified from liver samples using Trizol reagent
(Invitrogen) and then treated with DNase (10 U DNase I/g total RNA)
and reverse transcribed with a high-capacity cDNA reverse transcription
kit (Applied Biosystems) according to the manufacturer’s instructions.
Quantitative PCR amplifications were carried out in duplicate using
Power SYBR green PCR master mix (Applied Biosystems), 3 M primers,
and cDNA corresponding to 30 ng of total RNA input in a final volume of
10 l, in 384-well optical plates, using a 7900HT fast real-time qPCR
system (Applied Biosystems). The PCR primers were designed using
Primer express 3 software and synthesized by Qiagen or Sigma-Aldrich
(Lyon, France). Expression levels of target genes were normalized by com-
parison to expression of 18S rRNA. Results are expressed as 2–CT, re-
ferring to the fold induction in relation to the mean threshold cycle (CT)
obtained with noninfected WT mice.
Flow cytometry analyses. For flow cytometry analyses, livers were
perfused with phosphate-buffered saline (PBS) to remove blood cell con-
tamination prior to dissection. After homogenization of liver tissue and
elimination of hepatocytes by sedimentation, immune cells were purified
using 35% Percoll (GE Healthcare), and red blood cells were lysed. A total
of 106 leukocytes were incubated with anti-CD16/32 (BD Pharmingen) to
block nonspecific binding and washed. Cells were then incubated for
30 min with appropriate dilutions of anti-GR1-Pacific Blue (PB), anti-
CD11b-phycoerythrin (PE)-Cy7, anti-CD3-Pacific Blue, anti-CD8-
allophycocyanin (APC)-Cy7, anti-CD4-PE, anti-NP46-peridinin chloro-
phyll protein (PerCP)-Cy5.5, and anti-CD19-APC antibodies, all
purchased from BD Pharmingen. The staining of ST2 was assessed with a
rat monoclonal anti-mouse ST2-fluorescein isothiocyanate (FITC) anti-
body (clone DJ8; MB Bioproducts). Cells were washed, fixed in PBS con-
taining 2% fetal calf serum (FCS), 0.01 M sodium azide, and 2% formal-
dehyde, and analyzed by fluorescence-activated cell sorter (FACS) on an
Aria II flow cytometer using BD FACS Diva software (BD Bioscience), and
the data were processed using CXP software (Beckman Coulter). Dead
cells and doublet cells were excluded on the basis of forward and side
scatter. The different immune cell types were identified and gated as fol-
lows: B lymphocytes were CD19, NK cells were NP46 CD3, NKT cells
were NP46 CD3, T CD8 lymphocytes were NP46 CD3 CD8
CD4, and T CD4 lymphocytes were NP46 CD3 CD4 CD8. PMN
were GR1high CD11b, and macrophages were GR1int CD11b (see
Fig. S1 in the supplemental material). The macrophage gating strategy was
validated using an F4/80 antibody as previously described (53). Cell num-
bers per liver were calculated as follows: (no. of gated cells/no. of living
cells)  no. of infiltrating cells purified from the whole liver. ST2 expres-
sion and induction were quantified by the ratio of mean fluorescence
intensities (MFI) of ST2 to the MFI of control Ig-FITC in each gated cell
type.
Statistical analysis. Data are expressed as means  standard errors of
the means (SEM) for each group of mice (4 to 11 mice per group from 2 to
3 independent experiments). Differences between groups were analyzed
using the Student t test (human data) or the nonparametric Mann-
Whitney test (mouse data). A one-sample t test was used to confirm the
expression of ST2 observed by flow cytometry on different cell types as
follows: the MFI ratios were compared to 1, which is the value theoreti-
cally expected if there were no difference between a specific antibody and
its control isotype. Statistical analysis was performed using GraphPad
Prism 5.02 software. Differences were considered significant when the
P value was 0.05 and are indicated as follows: *, P  0.05; **, P  0.01;
and ***, P  0.001.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org
/lookup/suppl/doi:10.1128/mBio.00383-13/-/DCSupplemental.
Figure S1, TIF file, 7.6 MB.
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